Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg, a generic version of Renagel®1 Tablets, 400 mg and 800 mg, of Genzyme Corporation.
According to IQVIATM sales data for the 12 month period ending December 2018, the Renagel® Tablets, 400 mg and 800 mg market2 achieved annual sales of approximately $102.1 million*.
Glenmark's current portfolio consists of 149 products authorized for distribution in the U.S. marketplace and 53 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.616 as compared to the previous close of Rs. 639.1. The total number of shares traded during the day was 36181 in over 1242 trades.
The stock hit an intraday high of Rs. 644 and intraday low of 612. The net turnover during the day was Rs. 22441326.
1 All brand names and trademarks are the property of their respective owners.
2 Market includes brand and all available therapeutic equivalents
*IQVIATM National Sales Perspectives: Retail & Non-Retail, December 2018